Life sciences stories
Keeping customer and transaction data in-house, the software aims to cut the need for copied databases as firms train AI models.
Most life sciences manufacturers now see digital transformation as essential, with 54% reporting a cyberattack in the past year and many eyeing AI.
The construction consultancy's next phase of growth will be led by an internal appointee as it expands across 44 offices in 30 countries.
Europe's enterprise AI debate will centre on data sovereignty and governance as banks, drugmakers and universities gather in London.
Many security chiefs expect to curb AI agent use within 18 months as fears grow over unauthorised access and weak audit trails.
Lower running costs and faster output are aimed at businesses using Anthropic's latest Claude model, which starts at USD $4 per million input tokens.
Startups could file patent applications in days after Fearn raised USD $5.5 million to offer fixed-fee AI prosecution services.
More than a third of industrial decision-makers now see cyber risk as a top barrier to growth, a Rockwell survey found.
North American device makers seeking EU clearance may find compliance easier to track as DQS rolls out a digital review tool.
Despite faster AI adoption, firms in Oceania are still missing out on bigger returns because trust, governance and skills are lagging.
Rising complexity in temperature-sensitive drug shipments is driving Envirotainer to bring in a Maersk logistics veteran to steady growth.
AI-driven content growth is forcing larger firms to speed up compliance checks, as the New York start-up targets more sectors and regions.
The setup should ease cell therapy scale-up by giving developers industrial-grade control and more reproducible data before GMP production.
Britain's life sciences start-ups could get a lift as the British Business Bank injects GBP £135 million into two Advent funds.
The new group could help New Zealand researchers turn lab breakthroughs into medicines, materials and cleaner industrial processes faster.
Enterprise partners now face far less due diligence, after the health tech platform cut questionnaire length from 50 questions to single digits in weeks.
Researchers and startups will gain Claude API credits as the new funding backs cancer, heart disease and rare-disease work across Australia.
The grant backs an effort to overcome a key hurdle in mitochondrial medicine, where faulty genes remain hard to reach inside the organelle.
The five-day event will probe how Britain can turn research into scale-ups, with AI, quantum and defence policy all on the agenda.
The honour highlights Clinibase's rapid scaling, as its clinical trial software and recruitment teams now use live data to cut delays.
.webp)
